Skip to content
The Nexus
DossierENTITY

deramiocel

Coverage of deramiocel in the Nexus archive.

Earliest in view: May 8 · 13:37 UTCMost recent: Jul 29 · 21:45 UTC
Co-mentioned in this coverage
FDAorganization2Duchenne muscular dystrophytopic2cardiomyopathytopic1Capricor Therapeuticsorganization1Nippon Shinyakuorganization1NS Pharmaorganization1Alex Hoganperson1Lizzy Lawrenceperson1
Recent coverage
  • HEALTHJul 29 · 21:45 UTCMEDPAGE TODAY
    FDA Committee Votes Down Duchenne Drug

    An FDA panel voted 9-3 to reject the investigational drug deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy patients due to insufficient evidence of effectiveness.

  • HEALTHMay 8 · 13:37 UTCSTAT NEWS
    STAT+: The biotech news you need to read today

    Capricor Therapeutics is suing its partner Nippon Shinyaku over the launch of its Duchenne therapy, claiming they botched preparations and created an inaccessible pricing structure. The biotech company is fighting for its promising treatment, deramiocel. This lawsuit may impact the accessibility of the treatment for patients.